CDK16 and cancer: To further evaluate the regulation of PCTK1 in cancer cell phenotype and chemoresponse through BMPR1B-SMAD1/5/8 in CRC, we treated PCTK1-KD HT-29 cells with two SMAD1/5/8 inhibitors, LDN193189 and palovarotene.